Doximity's Growth Reset

🌾 Welcome to StableBread’s Newsletter!

Your doctor is probably on Doximity (NYSE:DOCS), the dominant digital network for U.S. medical professionals. Over 85% of U.S. physicians are verified members, and all top 20 U.S. hospitals are customers.

The stock traded near $75 in late 2025 and sits between $19-20 today, down ~64% YTD on a $3.5B market cap.

In the Q4 FY26 earnings release (on May 13, 2026), Doximity guided FY27 revenue to $664-676M (~4% growth at the midpoint) against a $697M consensus estimate. Adjusted EBITDA margin was guided to step down from 55.5% in FY26 to 49% in FY27.

Underneath the guide miss, three drivers stand out:

The main story is investor uncertainty on forward guidance, specifically revenue growth. It dropped from 13% in FY26 to a guided 4% in FY27, and the market repriced DOCS as if 4% is the new normal.

If DOCS rebounds to the $75 highs from late 2025, that's a 290%+ return from today's $19-20 lows. That's where the setup gets interesting, but whether the stock has any realistic chance of doing that is the focus of this write-up.

Doximity (DOCS), founded in 2010, operates a closed, identity-verified network for U.S. medical professionals.

Members use it for news, peer connection, telehealth (Dialer), on-call scheduling (Amion), secure messaging, digital fax, recruiting, and now clinical AI tools.

Network reach is effectively the entire asset. No other identity-verified physician network operates at the same scale.

DOCS sells subscription access to that network. Revenue mix in FY26 was ~95% subscription, ~5% other services.

Two customer types exist:

125 customers spending $500K+ on a TTM basis accounted for 83% of revenue in FY26, which carries some concentration risk.

If a single top-20 pharma client doesn't renew at the same scope or cuts mid-year supplemental buys, the growth narrative takes the hit.

Doximity reported Q4 FY26 results on May 13, 2026, for the quarter ending March 31, 2026.

The quarter beat on the top line. Revenue came in at $145.4M, up 5.1% y/y and above the high end of management's guidance. FCF hit $107.3M (+10.6% y/y), the first nine-figure FCF quarter in company history.

But profitability compressed. Adjusted EBITDA was $65.8M (down 5.6% y/y, 45.3% margin vs. 50.4%) as AI compute and R&D investment ramped.

The company also saw GAAP net income drop 69.4% to $19.1M. But this was almost entirely non-cash, from $36.7M of SBC and a $32.1M deferred tax adjustment. Non-GAAP diluted EPS landed at $0.26 vs. $0.38.

DOCS Q4 FY26 vs. Q4 FY25:

For the full fiscal year, Doximity hit records across the board: $645M revenue (+13% y/y), $358M adjusted EBITDA (+14% at 55.5% margin), and $317M FCF (+19% at 49.2% margin).

Then came the FY27 guide:

The revenue miss against consensus was the headline. More importantly, this is the first time Doximity has guided adjusted EBITDA lower in absolute dollars since the IPO.

The guide reads as a real reset, but most of the EBITDA compression is intentional spending, not deteriorating unit economics.

The bigger issue is revenue going from 13% to ~4% growth (discussed below), since that's the market repricing FY27 as the year Doximity loses its growth premium.

Doximity bought back $431.7M of stock in FY26 vs. $116M in FY25, a 3.7x increase.

That's driving an all-time high buyback yield of 12.74% ($431.7M FY26 buybacks / $3.39B market cap (Mar ‘26)).

The board has $493M remaining on the authorization as of March 31, 2026 (~14% of current market cap), and diluted share count has dropped 8.2% from 212.4M in Q1 FY24 to 195.0M in Q4 FY26.

Notably, buybacks are more attractive at $19 than at $75, since every dollar deployed retires ~4x more shares than at the late-2025 peak.

DOCS balance sheet is also healthy. Cash and marketable securities ended Q4 at $748.6M against $10.2M of operating lease liabilities and zero traditional debt. Net cash is $738.4M, or $3.80 per diluted share.

Doximity announced three personnel moves with the Q4 release:

One earlier departure worth noting is co-founder Nate Gross, who left Doximity in June 2025 to lead OpenAI's healthcare go-to-market. Months later, OpenAI launched ChatGPT Health in January 2026, a product that now competes directly with Doximity Ask for physician attention.

Sonefeldt is the most substantively interesting hire. He helped build LinkedIn's marketing solutions business, the closest comparable transition (network engagement to ad monetization) to what Doximity is now trying with AI Search.

Insiders Selling

Beyond the leadership changes, insider selling deserves a quick mention.

CEO Tangney's ~$75.7M sale in February 2025 stands out, though he still holds 2.1M+ shares directly per the Form 4.

Bryson and several directors also trimmed through 2025 and into 2026, all under 10b5-1 plans, so the timing wasn't opportunistic and isn't a major red flag on its own.

What’s more telling is that no executive has bought at these heavily discounted prices despite the stock being down ~75% from peak. Either management expects further downside, or they're letting the company's accelerating buyback do the work.

Five drivers explain DOCS’ repricing since late 2025.

Two sit on the income statement (FY27 guide undershoot and structural margin compression), two are external (AI competition and the Iran macro), and one is legal (the OpenEvidence litigation).

The FY27 guide reset growth from 13% to 4% with margins contracting alongside.

Quarterly revenue had been decelerating for two quarters before the guide hit:

Wall Street treated this as the start of a structural reset, not a one-year pause.

Price target (PT) cuts came in quickly:

Consensus PT is now $18 (low) to $47 (high) by May 2027. Of 22 analysts, 6 are Buy, 5 are Outperform, and 11 are Hold. None are Sell.

The margin guide is driven by spending choices, not pricing pressure. Three areas drive the EBITDA decline per the Q4 FY26 earnings call:

The SBC ramp is the most consequential. For a 4%-growth business, 20-23% of revenue in SBC is meaningful dilution.

Shareholders are effectively funding ~$140M of comp in FY27 against ~$25M of incremental revenue ($670M FY27 vs. $645M FY26).

You should expect SBC to either scale with revenue growth or fund something that drives future revenue. At 4% growth, neither really holds.

Management's AI narrative leans on the 800K active prescribers, 140 hospital deployments, and a 2-to-1 win rate in a 4,700-physician resident head-to-head. Those are real numbers.

But the competitive landscape is more crowded than the call let on.

Specifically, OpenEvidence, the “ChatGPT for doctors,” has ~650K active U.S. physician users plus another 1.2M international. Doximity has ~250-300K HIPAA-compliant Clinical AI Suite users.

OpenEvidence also won Mount Sinai Epic enterprise-wide deployment in March 2026 and Sutter Health Epic in February 2026. Once a hospital system standardizes a clinical AI tool inside Epic (the dominant EHR), switching costs are high and the tool gets surfaced at the moment of a prescription decision.

That locks OpenEvidence into the Mount Sinai and Sutter workflows, and makes it hard for Doximity to displace at those institutions.

If the pattern continues across more health systems, Doximity's AI distribution stays outside the EHR, at a less valuable surface for pharma ad targeting.

Not to mention, general-purpose LLMs (ChatGPT, Gemini, Claude) are widely accessible and improving every quarter.

Per Tangney on the Q4 call, ~50% of doctor queries on Doximity Ask contain protected health information (PHI), which gives Doximity a defensible moat in that bucket. The other ~50% (non-PHI queries) is in commoditization range against free LLMs.

ChatGPT Health is the newest threat here. It launched in January 2026 and, as previously discussed, sits inside the OpenAI healthcare unit that Doximity co-founder Nate Gross now leads.

VP IR Perry Gold flagged the Iran war on the call:

This matters for Doximity because ~85% of revenue comes from pharma marketing. When pharma supply chains get squeezed, marketing budgets are one of the first lines to tighten or shift to shorter-duration commitments.

Currently, India supplies ~47% of U.S. generic prescriptions and relies on the Strait of Hormuz for ~40% of its crude oil imports. ~90% of critical or life-saving pharmaceuticals move by air, with Gulf air-cargo rates spiking up to 350% in early 2026.

There's also direct drug-pricing pressure. The Trump administration's Most-Favored-Nation (MFN) drug pricing policy has reached agreements with 17 of the largest pharma manufacturers, projected to save ~$529B over the next decade.

Pharma is signing under tariff-threat leverage. Lower drug prices squeeze pharma margins, and tighter margins flow into marketing budgets, which is where DOCS generates 85% of its revenue.

Falling NRR

Pull back from the macro for a second, and the slowdown is already visible in the numbers:

109% NRR still means existing customers are spending ~9% more on a TTM basis.

The problem is that a network platform earns its premium multiple by expanding existing accounts faster than the market grows, and a 10-point drop says that engine is weakening.

If Doximity is no longer taking share, the multiple should reset to a market-tracking software multiple, not a growth-oriented one.

OpenEvidence, Doximity's main clinical AI competitor, sued Doximity, its CTO, and its Director of AI Products in U.S. District Court (Massachusetts) on June 20, 2025.

The allegation is that Doximity executives ran "prompt injection" attacks against OpenEvidence's AI, and used what they extracted to improve Pathway Medical, which Doximity later acquired for $63M and integrated into the Clinical AI Suite.

The case has advanced past dismissal. On January 22, 2026, the court denied Doximity's motion to dismiss on most of OpenEvidence's claims (including under the Defend Trade Secrets Act and the Computer Fraud and Abuse Act).

The litigation is now in discovery, and Doximity has counter-claimed for false advertising and defamation.

Likelihood of success is hard to call before discovery, but the surviving claims are substantive enough that the case is unlikely to settle for nuisance value.

Tech trade-secret settlements have ranged widely. The largest recent benchmark is Waymo v. Uber's ~$245M settlement in 2018; most others land in the tens of millions. A settlement in the $50-200M range would be ~1-6% of DOCS’ $3.5B market cap.

The bigger risk is an injunction. An adverse ruling could force Doximity to redesign or replace the Pathway technology, which currently powers Doximity Ask and the AI Search product.

That could delay AI Search monetization by 6-12 months, dent customer trust during the pharma pitch cycle, and hand competitive ground back to OpenEvidence.

Adding more U.S. physicians has slowed as a growth channel for Doximity. The company went from 80% physician coverage to only 85% over 4 years. Future growth will probably come from somewhere else.

The remaining levers are: